1 5 1

generated using probit analysis. A steep dose response effect was found. The predic- ted E.D. value for 50% incidence was approx- imately 990 with a standard error of +30.

This E.D. value is equivalent to an avera- ge lung dose of 3270 cGy in 15 fractions. This dose response curve emphasises the need for accuracy in clinical dosimetry, as a 10% increase in dose predicts for a 30% increase in the incidence of acute lung damage.

Radiosensitivity of Human Lung Cancer Cells Grown in Nude Mice a~d in Culture. Miyamot~, T., Momiki x, S., Ohara, S., Ya- maguchi-, Y., Tunemoto, H. National Insti- tute of Radiological Sciences. i. Insti- tute of Pulmonary Cancer Research, Chiba University, Chiba City, Japan.

For the quantitive determination of radiosensitivity of human lung cancer, the tumors and cells obtained from 43 patients with primary lung cancer have been hetero- transplanted into nude mice primed with x- -ray at 4 to 5 Gy. These tumor cells also have been cultivated IN VITRO. As a result, we have established 17 (40%) nude tumors (adeno.; i0, epidermoid; 4, small; 2, large; i) and 7 (18%) culture cell lines (adeno.; 2, epidermoid; i, small; 3, large; l). Three of the nude tumors and 3 of the culture lines were used to obtain a dose- survival curve (DRC) for x-ray by using a regrowth and colony assay technique, respec- tively.

Nude Tumor Culture Cell (Gy) adeno, adeno, larse adeno, adeno L~rge

Dq 4.8 2.0 1.2 3.5 2.5 0 ,2

D. 2 .8 2 ,8 2 .2 1 ,0 1 .2 0 , 8

1. Radioresistance of adenocarcinoma of the lung was more dependent on Dq of DRC for x-ray than D.

2. D of DRC of the IN VIVO (nude tumor) ce°lls for x-ray was about 2 to 3 times higher than that of the culture cells.

9, CO~INED TREATMENT MODALITIES

Survival in Lung Cancer According to Treat- ment Modality: Results of 327 Patients From 1982 in One Institution. Hawson, G.A.T., Zimmerman, P.V. The Prince Charles Hospital, Queensland, Australia, 4032.

Survival figures for 327 patients with primary lung malignancy out of a total of 366 malignancies recorded in a computerized data base (50% of the total for the State) from a single Australian referral centre are presented for the year 1982. Follow up for a two, to three year period has been obtained from the Cancer Registry. At this stage 76% of patients have died.

Survival was not related to histological

subtype (except small cell). RADICAL RADIO-

THERAPY was given to patients with surgically

inoperable, localised tumours of small bulk. SURGERY was performed in patients whose pre- operative evaluation demonstrated localised disease and who were considered medically fit. CHEMOTHERAPY was given to almost all E.C.O.G. performance status 0-3 but only two non small cell patients were treated.

SURVIVAL no. 1 yr % 2 yr % median

Surgery 53 77 60 25 Radiotherapy Radical 76 61 30 14 Palliative 52 27 13 7

Chemotherapy 31 55 16 12 Palliation 92 22 13 3

The contribution to survival of a number of other prognostic indicates including T.N.M. staging, performance status, Feinstein index and weight loss will be presented.

Radiotherapy Versus Chemotherapy as Initial Therapy in Non-Resectable Non-Small Cell Car- cinoma of the Ltmg (NSCCL). II Quality of Life

Studi~s. 2 3 Kaasa , ~., Nmss , S., Ol~nes , B.T. Thorud I, E., H~st-, H., Mastekaasa , A., Lund ~, E. i. General Department, The Norwegian Radium Hos- pital. 2. Institute of Applied Social Research. 3. Neuropsychological Sect., XIV Department, Oslo City Hospital, Oslo, Norway.

Little attention has been paid to quality of life studies in patients subjected to in- tensive treatment by radiation and/or chemo- therapy. In the present study 60 patients with non-resectable non-small cell cancer of the lung were randomized to either radiothe- rapy (2,8 Gy x 15) or combination chemotherapy (cis-platin, etoposide). Assessment of the quality of life was performed at start of tre- atment, during and at certain intervals after treatment by:

i) psycho-social life evaluation, 2) neuro- psychological fundation test, 3) performance status evaluation and 4) therapeutic side ef- fects.

All patients have been followed for at least 12 months. The response rates and the survival in the two treatment arms have been compared and related to the effect on the quality of life. The immediate toxicity was most pronoun- ced following chemotherapy.

Radiotherapy (RT) Combined With Cisdiammine- Dichloroplatinum (cDDP) as Radioenhancer in a Dose Escalating Way, in Non Small Cell Lung Cancer (NSCLC) I 1+2 Schaake-Koning , C.,2van Zandwijk 2 , N., Schu~ter-Uitterhoeve , L., Koolen , M., Barte- link , H. i. The Netherlands Cancer Institute. 2. The Academic Medical Centre, Amsterdam, The Netherlands.

There is growing evidence that cDDP can en- hance the effects of RT on tumor cells in vi-

tro. In order to establish the maximum dose of